Melphalan intraocular injection - EyePoint Pharmaceuticals

Drug Profile

Melphalan intraocular injection - EyePoint Pharmaceuticals

Latest Information Update: 05 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EyePoint Pharmaceuticals; Icon Bioscience
  • Developer Icon Bioscience
  • Class Antineoplastics; Aromatic amino acids; Myeloablative agonists; Nitrogen mustard compounds; Small molecules
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinoblastoma
  • New Molecular Entity No

Highest Development Phases

  • No development reported Retinoblastoma

Most Recent Events

  • 28 Mar 2018 Icon Bioscience has been acquired by EyePoint Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Retinoblastoma in USA (Intraocular, Controlled release)
  • 03 Jan 2013 Icon Bioscience's controlled-release intraocular injection formulation of Melphalan receives Orphan Drug status for Retinoblastoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top